Russia's 'Sputnik V' Vaccine Spray Form Phase 2 Clinical Trial
[Asia Economy Reporter Seulgina Jo] Russian authorities have approved the phase 2 clinical trial (phase 2) of the spray-type version of the COVID-19 vaccine 'Sputnik V,' Interfax news agency reported on the 12th (local time).
According to the news agency, the Russian Ministry of Health approved the phase 2 trial of the spray-type Sputnik V vaccine the day before. The phase 2 trial will be conducted at the 'Eco-Safety Research Center' in Saint Petersburg until December 31, 2023. The spray-type Sputnik V vaccine requires two doses.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Don't Throw Away Coffee Grounds" Transformed into 'High-Grade Fuel' in Just 90 Seconds [Reading Science]
- "Am I Really in the Top 30%?" and "Worried About My Girlfriend in the Bottom 70%"... Buzz Over High Oil Price Relief Fund
- The Unexpected Story of an American Man Who Won the Lottery 18 Times in 29 Years: "My Real Luck Is My Wife"
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Sputnik V is a vector-based vaccine created by inserting the COVID-19 virus gene into a harmless carrier (vector), the cold adenovirus. Currently, 70 countries, including Russia, have approved the use of the Sputnik V vaccine.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
